Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (2535)	10/25/2010 1:06:10 AM
From: tuck	Read Replies (4) \| Respond to of 3027

Since the fairly significant sales beat by m-enoxaparin last week I have seen no analysts upgrade, reiterate or quietly raise estimates. The current consensus of of a 5 cent loss is way off, IMO. I think MNTA will make somewhere between 40 and 80 cents (we don't know all the variables with certainty). Many posts about this at Ihub lately. Momenta pooped slightly on the news, but I have a strong conviction that there is still considerable upside going into earnings, and that the stock should approach $20 again. With that in mind, I am planning on cashing my trading shares for calls tomorrow. FWIW. Cheers, Tuck